IMR Press / CEOG / Volume 38 / Issue 1 / pii/1630488470238-1503021922

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

A practical approach to the prevention of miscarriage: Part 5 – antiphospholipid syndrome as a cause of spontaneous abortion
Show Less
1 The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2011, 38(1), 5–9;
Published: 10 March 2011

Purpose: To describe the diagnosis and treatment of antiphospholipid syndrome as it relates to spontaneous abortion. Methods: The relative importance of performing tests of antiphospholipid antibodies that prolong the partial thromboplastin time and other autoantibodies against phospholipids measured by ELISA are discussed. Results: The most important diagnostic tests are the lupus anticoagulant, anticardiolipin antibody and antiphosphatidyl serine. Low molecular weight heparin and low dose aspirin are the two most important therapies. Conclusions: Women with recurrent miscarriages or even an unexplained miscarriage especially after ten weeks (but sometimes even early first trimester) or a history of thrombosis or intrauterine growth restriction and maybe preeclampsia are candidates for anticoagulant therapy, especially with the presence of significant levels of the lupus anticoagulant or anticardiolipin or antiphosphatidyl serine antibodies (> 40 pl units/ml).;">
Antiphospholipid antibodies
Lupus anticoagulant
Spontaneous abortion
Low molecular weight heparin
Back to top